Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis C and PIs.

H Albrecht1

  • 1Division of Infectious Diseases, Emory University School of Medicine, Atlanta, USA.

AIDS Clinical Care
|October 10, 2001
PubMed
Summary
This summary is machine-generated.

Treatment with protease inhibitor (PI)-containing regimens in patients with HIV and Hepatitis C virus (HCV) coinfection was linked to reduced liver fibrosis and slower cirrhosis progression. This finding highlights potential benefits for managing coinfected individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A national evaluation of the implementation of guideline recommendations towards antibiotic prophylaxis prior to percutaneous endoscopic gastrostomy and jejunostomy tube placement.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2025
Same author

Multicenter analysis of endoclot as hemostatic powder in different endoscopic settings of the upper gastrointestinal tract.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2021
Same author

Anticoagulant-related gastrointestinal bleeding: a real-life data analysis on bleeding profiles, frequency and etiology of patients receiving direct oral anticoagulants versus vitamin K antagonists.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2020
Same author

Happiness in dermatology: a holistic evaluation of the mental burden of skin diseases.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Same author

Endoscopic full-thickness resection (EFTR) in the lower gastrointestinal tract.

Techniques in coloproctology·2019
Same author

Laparoscopic sphincter reconstruction after abdominoperineal resection: feasibility and technical aspects.

Techniques in coloproctology·2019
Same journal

Report from the 2008 joint ICAAC/IDSA meeting. Bevirimat: predictors of response.

AIDS clinical care·2009
Same journal

Report from the 2008 joint ICAAC/IDSA meeting. Maraviroc vs. efavirenz: a reanalysis of MERIT.

AIDS clinical care·2009
Same journal

Report from the 2008 joint ICAAC/IDSA meeting. More on raltegravir: resistance and mechanisms of action.

AIDS clinical care·2009
Same journal

Report from the 2008 joint ICAAC/IDSA meeting. Raltegravir vs. efavirenz in treatment-naive patients.

AIDS clinical care·2009
Same journal

A single case of cure?

AIDS clinical care·2009
Same journal

Darunavir now approved for use in treatment-naive patients.

AIDS clinical care·2009
See all related articles

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Clinical Pharmacology

Background:

  • Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease, particularly in patients coinfected with human immunodeficiency virus (HIV).
  • Liver fibrosis and cirrhosis represent significant complications in HIV/HCV coinfected individuals, impacting morbidity and mortality.
  • Protease inhibitor (PI)-containing antiretroviral regimens are standard care for HIV, but their impact on HCV-related liver disease progression is an area of ongoing investigation.

Discussion:

  • This retrospective analysis investigated the association between PI-containing regimens and liver disease progression in a large cohort of HIV/HCV-coinfected patients.
  • The study evaluated fibrosis scores and the rate of progression to cirrhosis as key outcome measures.
  • Findings suggest a potential disease-modifying effect of PI-based therapies on HCV-induced liver damage.

Related Experiment Videos

Key Insights:

  • Treatment with protease inhibitor (PI)-containing regimens was associated with significantly lower liver fibrosis scores in HIV/HCV-coinfected patients.
  • Patients on PI-containing regimens demonstrated a slower rate of progression toward cirrhosis compared to those on other regimens.
  • These results indicate a potential protective effect of PIs against advanced liver disease in this vulnerable population.

Outlook:

  • Further prospective studies are warranted to confirm these findings and elucidate the underlying mechanisms.
  • Investigating the optimal timing and duration of PI-containing regimens for mitigating liver fibrosis in HIV/HCV coinfection is crucial.
  • This research may inform treatment guidelines and improve long-term outcomes for coinfected patients.